USPTO Extends Cancer Immunotherapy Pilot Program The United States Patent and Trademark Office recently issued a notice extending the Cancer Immunotherapy Pilot Program (AKA “Patents 4 Patients”) until September 30, 2022. The program was first implemented in 2016 as part of the $1 billion National Cancer Moonshot initiative and allows for fast-track review of cancer immunotherapy-related patent applications without the need […] Read Post →
USPTO Issues Final Rule Amending Rules of Practice For Biological Sequence Listings On May 20th, the United States Patent and Trademark Office published a Final Rule amending the rules of practice associated with disclosures of nucleotide and amino acid sequences in patent applications. The new standards, applicable to all patent applications filed on or after July 1, 2022, will bring the USPTO rules of practice into conformity […] Read Post →